Teva Pharmaceutical Industries (NYSE:TEVA) Shares Down 5.1% - Should You Sell?

Key Points

• Teva Pharmaceutical Industries' shares fell 5.1% to $18.91 amid fluctuating trading volume, significantly below the average session volume.
• Wall Street analysts have varied opinions with several rating the stock as a buy, including Goldman Sachs who set a price target of $24.00, while UBS reduced its target to $23.00.
• Teva's latest earnings report showed a profit of $0.66 per share, beating estimates, but revenue was slightly below expectations at $4.18 billion.

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Get Free Report)'s stock price traded down 5.1% during mid-day trading on Monday . The stock traded as low as $18.99 and last traded at $18.91. 9,188,954 shares traded hands during mid-day trading, a decline of 23% from the average session volume of 11,960,685 shares. The stock had previously closed at $19.93.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on the company. Wall Street Zen raised Teva Pharmaceutical Industries from a "hold" rating to a "buy" rating in a research report on Saturday, July 26th. The Goldman Sachs Group assumed coverage on Teva Pharmaceutical Industries in a research report on Friday, June 6th. They issued a "buy" rating and a $24.00 price target on the stock. UBS Group lowered their price target on Teva Pharmaceutical Industries from $24.00 to $23.00 and set a "buy" rating on the stock in a research report on Thursday, June 26th. Finally, Truist Financial started coverage on Teva Pharmaceutical Industries in a research report on Wednesday, May 28th. They issued a "buy" rating and a $25.00 price target on the stock. Two equities research analysts have rated the stock with a Strong Buy rating and six have given a Buy rating to the company's stock. Based on data from MarketBeat, Teva Pharmaceutical Industries currently has a consensus rating of "Buy" and an average target price of $24.71.

Teva Pharmaceutical Industries Trading Down 5.2%

The firm has a market capitalization of $21.68 billion, a price-to-earnings ratio of -118.13, a P/E/G ratio of 1.16 and a beta of 0.72. The business has a 50-day moving average of $17.35 and a two-hundred day moving average of $16.52. The company has a quick ratio of 0.77, a current ratio of 1.06 and a debt-to-equity ratio of 2.45.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last released its earnings results on Wednesday, July 30th. The company reported $0.66 earnings per share for the quarter, topping analysts' consensus estimates of $0.64 by $0.02. Teva Pharmaceutical Industries had a positive return on equity of 46.10% and a negative net margin of 0.95%.The business had revenue of $4.18 billion for the quarter, compared to the consensus estimate of $4.34 billion. During the same period last year, the business earned $0.61 earnings per share. The firm's revenue for the quarter was up .3% compared to the same quarter last year. Teva Pharmaceutical Industries has set its FY 2025 guidance at 2.500-2.600 EPS. Research analysts predict that Teva Pharmaceutical Industries Ltd. will post 2.5 EPS for the current fiscal year.

Insider Buying and Selling

In other Teva Pharmaceutical Industries news, insider Eric A. Hughes sold 52,742 shares of Teva Pharmaceutical Industries stock in a transaction that occurred on Friday, August 1st. The stock was sold at an average price of $15.16, for a total transaction of $799,568.72. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, insider Placid Jover sold 6,053 shares of Teva Pharmaceutical Industries stock in a transaction that occurred on Friday, August 1st. The shares were sold at an average price of $15.16, for a total value of $91,763.48. Following the sale, the insider directly owned 6,774 shares in the company, valued at $102,693.84. The trade was a 47.19% decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.55% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of TEVA. Ameriprise Financial Inc. raised its stake in shares of Teva Pharmaceutical Industries by 3.9% in the fourth quarter. Ameriprise Financial Inc. now owns 147,649 shares of the company's stock valued at $3,254,000 after acquiring an additional 5,494 shares during the last quarter. Focus Partners Wealth raised its stake in shares of Teva Pharmaceutical Industries by 8.7% in the fourth quarter. Focus Partners Wealth now owns 38,335 shares of the company's stock valued at $845,000 after acquiring an additional 3,071 shares during the last quarter. Jefferies Financial Group Inc. bought a new position in shares of Teva Pharmaceutical Industries in the fourth quarter valued at approximately $332,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in shares of Teva Pharmaceutical Industries by 122.2% in the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 10,048 shares of the company's stock valued at $221,000 after acquiring an additional 5,526 shares during the last quarter. Finally, Nuveen Asset Management LLC raised its stake in shares of Teva Pharmaceutical Industries by 6.8% in the fourth quarter. Nuveen Asset Management LLC now owns 2,857,007 shares of the company's stock valued at $62,968,000 after acquiring an additional 182,774 shares during the last quarter. Institutional investors own 54.05% of the company's stock.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.